<DOC>
	<DOC>NCT01050998</DOC>
	<brief_summary>The primary objectives of this study is to assess the safety, tolerability and efficacy of multiple doses of the mavrilimumab (CAM-3001) administered subcutaneously in subjects with moderately active Rheumatoid Arthritis (RA).</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description>This is a Phase 2, randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate the efficacy and safety of multiple doses of the mavrilimumab (CAM-3001) (10 milligram [mg], 30 mg, 50 mg, and 100 mg) administered subcutaneously in adult subjects with moderately active RA.</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Age 18 through 80 years (20 to 75 years in Japan) Written consent Diagnosis of adult onset Rheumatoid Arthritis (RA) of at least 3 months duration as defined by the 1987 American College of Rheumatology (ACR) classification criteria (Arnett et al, 1988) Treatment with methotrexate at a stable and tolerated doses Positive anticyclic citrullinated peptide (CCP) immunoglobulin G antibodies (more than [&gt;] 5 international unit per milliliter [IU/mL]) and/or rheumatoid factor (RF &gt;14 IU/mL) at screening Received more than or equal to (&gt;=) 5 milligram (mg) per week folic acid as a single or divided dose during the study. A rheumatic autoimmune disease other than RA A history of, or current, inflammatory joint disease other than RA or other systemic autoimmune disorder Subjects at a high risk of infection Subjects (male and female) of reproductive potential who are not willing to use contraception from screening through the end date of the trial History of methotrexate or any druginduced lung fibrosis or pneumonitis.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Mavrilimumab</keyword>
	<keyword>CAM-3001</keyword>
</DOC>